Cargando…
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
Aim: Evaluate efficacy/safety of bremelanotide (BMT), a melanocortin-receptor-4 agonist, to treat female sexual dysfunctions in premenopausal women. Methods: Patients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks. Primary end p...
Autores principales: | Clayton, Anita H, Althof, Stanley E, Kingsberg, Sheryl, DeRogatis, Leonard R, Kroll, Robin, Goldstein, Irwin, Kaminetsky, Jed, Spana, Carl, Lucas, Johna, Jordan, Robert, Portman, David J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384512/ https://www.ncbi.nlm.nih.gov/pubmed/27181790 http://dx.doi.org/10.2217/whe-2016-0018 |
Ejemplares similares
-
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
por: Simon, James A., et al.
Publicado: (2019) -
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
por: Kingsberg, Sheryl A., et al.
Publicado: (2019) -
Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder
por: Revicki, Dennis A., et al.
Publicado: (2020) -
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials
por: Spana, Carl, et al.
Publicado: (2022) -
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide
por: White, William B., et al.
Publicado: (2017)